Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...

Researchers in Class of 1942 Professor of Chemistry Matthew D. Shoulders' lab have uncovered a sinister hidden mechanism that ...

The GOG 3026 trial demonstrated that ribociclib and letrozole combination therapy achieved a 31% response rate and 84% ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...

HHMI Investigator Kevan Shokat and his lab are charting new therapies to outmaneuver drug resistance and better target common cancer cell mutations.

A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.

High-grade serous ovarian cancer remains a primary focus in gynecologic oncology; however, low-grade serous ovarian cancer ...

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the first time, in a study led by investigators at Weill Cornell Medicine and the ...

GMCL1-dependent degradation of 53BP1 suppresses mitotic surveillance, tuning p53 activation thresholds that govern cell fate decisions and cellular responses after mitosis.

Next-generation BTK protein degrader APG-3288 receives IND clearance from the U.S. FDA, propelling expansion of global innovative pipeline ROCKVILLE, Md. and SUZHOU, China, Jan. 14, 2026 (GLOBE ...

In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...